Biopsy-confirmed leukocytoclastic vasculitis following insurance-mandated switch from dupilumab to lebrikizumab in a patient with severe atopic dermatitis
Biopsy-confirmed leukocytoclastic vasculitis following insurance-mandated switch from dupilumab to lebrikizumab in a patient with severe atopic dermatitis. // JAAD Case Reports. – URL: https://www.sciencedirect.com/science/article/pii/S2352512626006156?dgcid=rss_sd_all
Biopsy-confirmed leukocytoclastic vasculitis following insurance-mandated switch from dupilumab to lebrikizumab in a patient with severe atopic dermatitis. JAAD Case Reports. https://www.sciencedirect.com/science/article/pii/S2352512626006156?dgcid=rss_sd_all
“Biopsy-confirmed leukocytoclastic vasculitis following insurance-mandated switch from dupilumab to lebrikizumab in a patient with severe atopic dermatitis.” JAAD Case Reports.
@article{article50411,
title = {Biopsy-confirmed leukocytoclastic vasculitis following insurance-mandated switch from dupilumab to lebrikizumab in a patient with severe atopic dermatitis},
journal = {JAAD Case Reports},
url = {https://www.sciencedirect.com/science/article/pii/S2352512626006156?dgcid=rss_sd_all}
}